Sanofi SAN.PA · Stock Open Sanofi in new tab
Analyst price targets
Recent rating changes, newest first
Sanofi Analysis (SAN.PA)
Is Sanofi a good investment? Sanofi (SAN.PA) is currently trading at 71.60 EUR. Market analysts have a consensus price target of 94.06 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 22.14. This valuation is generally in line with the broader market.
Earnings Schedule: Sanofi is expected to release its next earnings report on Oct. 30, 2026. The market consensus estimate for Forward EPS is 9.06.
For income investors, Sanofi pays a dividend yield of 11.61%. With a payout ratio of 124%, the dividend appears to be under pressure.
Investor FAQ
Does Sanofi pay a dividend?
Yes, it pays an annual dividend of 8.33 EUR (11.61% yield).
What asset class is Sanofi?
Sanofi is classified as a Stock. You can compare it against 21 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Oct. 30, 2026. The company currently has a trailing EPS of 3.22.
Company Profile
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Year | Total Dividends |
|---|---|
| ▸2027 |
4.24 EUR
|
| May 17, 2027 (estimated) | 4.2364 |
| ▸2026 |
4.12 EUR
|
| May 7, 2026 | 4.1200 |
| ▸2025 |
3.92 EUR
|
| May 14, 2025 | 3.9200 |
| ▸2024 |
3.76 EUR
|
| May 15, 2024 | 3.7600 |
| ▸2023 |
3.56 EUR
|
| June 1, 2023 | 3.5600 |
| ▸2022 |
3.33 EUR
|
| May 10, 2022 | 3.3300 |
| ▸2021 |
3.20 EUR
|
| May 7, 2021 | 3.2000 |
| ▸2020 |
3.15 EUR
|
| May 6, 2020 | 3.1500 |
| ▸2019 |
3.07 EUR
|
| May 13, 2019 | 3.0700 |
| ▸2018 |
3.03 EUR
|
| May 15, 2018 | 3.0300 |
| ▸2017 |
2.96 EUR
|
| May 18, 2017 | 2.9600 |
| ▸2016 |
2.93 EUR
|
| May 12, 2016 | 2.9300 |
| ▸2015 |
2.85 EUR
|
| May 13, 2015 | 2.8500 |
| ▸2014 |
2.80 EUR
|
| May 15, 2014 | 2.8000 |
| ▸2013 |
2.77 EUR
|
| May 14, 2013 | 2.7700 |
| ▸2012 |
2.65 EUR
|
| May 15, 2012 | 2.6500 |
| ▸2011 |
2.50 EUR
|
| June 16, 2011 | 2.5000 |
| ▸2010 |
2.40 EUR
|
| May 25, 2010 | 2.4000 |
| ▸2009 |
2.20 EUR
|
| April 28, 2009 | 2.2000 |
| ▸2008 |
2.07 EUR
|
| May 21, 2008 | 2.0700 |
| ▸2007 |
1.75 EUR
|
| June 7, 2007 | 1.7500 |
| ▸2006 |
1.83 EUR
|
| Nov. 29, 2006 | 0.3100 |
| June 7, 2006 | 1.5200 |
| ▸2005 |
1.48 EUR
|
| Nov. 29, 2005 | 0.2800 |
| June 7, 2005 | 1.2000 |
| ▸2004 |
1.02 EUR
|
| Sept. 30, 2004 | 0.0500 |
| May 5, 2004 | 0.9700 |
| ▸2003 |
0.84 EUR
|
| June 2, 2003 | 0.8400 |
| ▸2002 |
0.66 EUR
|
| June 3, 2002 | 0.6600 |
| ▸2001 |
0.44 EUR
|
| June 1, 2001 | 0.4400 |
| ▸2000 |
0.32 EUR
|
| June 5, 2000 | 0.3200 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Sanofi | May 07, 2026 | Paid | 4.12 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| June 10, 1991 | 1.029 |
| June 5, 1992 | 1.022 |
| Sept. 27, 1994 | 4:1 |
| Oct. 2, 1995 | 1.1 |
| May 25, 1999 | 4:1 |
Community Discussion